Patients who identified a dose that produced satisfactory PR for at least two target breakthrough pain episodes were eligible to enter the double-blind crossover period.
Long-acting oral morphine was used in 23.8% of patients for persistent pain and short-acting oral morphine was used in 26.5% of patients for target breakthrough pain.
The most common stable opioid regimen was transdermal fentanyl for persistent pain, taken by 46.4% of patients, and hydrocodone for target breakthrough pain, taken by 42.4% of patients.
For approximately half of the patients in the safety population, the pain pathophysiology for both persistent pain and target breakthrough pain was somatic and/or visceral.
Any subsequent dose of study medication was for the emergence of a new target breakthrough pain episode and not an unresolved previously treated episode.
For most patients in the safety population, the pain syndrome for persistent and target breakthrough pain was typically related to direct tumor involvement (84.8% and 86.1% of patients, respectively) or due to somatic/visceral lesions (83.4% and 84.8% of patients, respectively).
Such "exo-Earths" (habitable zone exoplanets) are among the primary targets for Breakthrough Listen, and Proxima b is the primary target for Breakthrough Listen's sister initiative, Breakthrough Starshot, which is developing the technology to send gram-size spacecraft to nearby stars.
Although many new agents have been developed aimed at putative molecular targets, recent breakthroughs in therapy for advanced disease have arisen from our ability to safely give patients combination cytotoxic chemotherapy.
Similarly, support for R&D is critical to lowering long-run decarbonization costs, and typically targets technological breakthroughs in different economic sectors.
The pathway of drug discovery from gene and therapeutic targets to breakthrough medicines provides an extraordinary adventure that often includes high risks, creative insights, relentless perserverance, goal-oriented focus, interdisciplinary teamwork and a bit of good luck.
Therefore, the novel functions of TERT represent promising targets for achieving breakthroughs in anticancer treatments targeting TERT, which would be of benefit to many patients with malignant disease.
